Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · December 19, 2024

Factors Associated With Maintenance of Clinical Response After Reducing the Dosing Frequency of Tralokinumab in Patients With Moderate to Severe Atopic Dermatitis

The British Journal of Dermatology

 

Additional Info

The British Journal of Dermatology
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
Br J Dermatol 2024 Dec 05;[EPub Ahead of Print], S Weidinger, A Bewley, HC Hong, JF Silvestre, K Peris, A Wollenberg, U Ivens, A Soehoel, LA Steffensen, AM Tindberg, EL Simpson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading